Assessment of GeneXpert MTB/RIF performance for tuberculosis at doctor chasbullah abdulmajid hospital, bekasi city

Tuberculosis (TB) remains a critical global health threat, with effective detection methods continuing to pose challenges. Since 2012, the Indonesian National TB Control Program has utilized the GeneXpert examination with the Xpert MTB/RIF (Mycobacterium Tuberculosis/Rifampicin) cartridge, enabling rapid identification of Mycobacterium tuberculosis (MTB) and simultaneous detection of rifampicin resistance. This descriptive study assesses the performance of the GeneXpert MTB/RIF assay in patients at Doctor Chasbullah Abdulmajid Hospital. Results were classified into successful tests (MTB detected, MTB not detected, MTB detected with rifampicin resistance, and MTB detected with rifampicin indeterminate) and failed tests (invalid, error, and no result). Data were sourced from the National Tuberculosis Information System (SITB), comprising 2,408 patients who met the inclusion criteria. The findings indicate that most suspected TB patients were between 19 and 44 years old (36.62%), with a higher prevalence in males (58.39%) than in females (41.6%). The majority were new TB cases (88.88%). The GeneXpert MTB/RIF assay exhibited an impressive 99.8% success rate, alongside a failure rate of 0.12%. Among successful tests, 30.06% detected MTB, with 26.61% being rifampicin-sensitive and 3.44% resistant. Notably, 69.80% of tests resulted in undetectable MTB. Error results may arise from various factors, including undetectable MTB DNA and system malfunctions. While a significant number of negative results were observed, these findings merit further investigation, particularly in suspected pediatric TB cases.